Acute Coronary Syndrome
Conditions
Keywords
ACS, PCI
Brief summary
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI. Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve target ACT.
Detailed description
MT1002 is a novel 32-amino acid synthetic peptide aimed to combine molecular functions of both a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa receptor antagonist, indicated for use as an antithrombotic and anticoagulant in patients with ACS and in patients undergoing PCI. This study is to investigate the safety, tolerability, and efficacy of MT1002 in patients undergoing PCI due to ACS with NSTEMI. This study is a single dose, sequential-dose escalation study in patients undergoing PCI due to ACS with NSTEMI. The first 2 doses were considered safe and well tolerated in the Phase 1 healthy subject study. The third dose to be given will be determined based on the safety and efficacy results from the first 2 doses. Dose escalation/de-escalation and stopping rules have been put in place to ensure the safety of the patients in this study. The patients will receive a single MT1002 close to the initiation of PCI (Day 1) followed by 4 hours of IV infusion and follow-up at Day 2, Day 14, and Day 30.
Interventions
MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
Sponsors
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open-Label, Sequential-Dose Escalation/De-escalation Trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Males and females ≥ 18 to 85 years of age. 2. Diagnosed with NSTEMI. 3. Patients who will undergo PCI during the index hospitalization for an NSTEMI. 4. Ability to understand and willing to give written informed consent. 5. Women of childbearing potential must have a negative pregnancy test or be post-menopausal for at least 1 year before enrollment or be permanently sterilized since ≥6 weeks. Females of childbearing potential and males with partners of childbearing potential must be using effective contraception.
Exclusion criteria
1. .Cardiogenic shock or prolonged cardiopulmonary resuscitation (CPR). 2. Active bleeding, bleeding diathesis, coagulopathy. 3. Any history of intracranial bleeding or structural abnormalities. 4. Prior transient ischemic attack, prior stroke within 6 months. 5. Index MI is STEMI or new left bundle branch block. 6. The following planned procedures within 30 days after enrollment: staged PCI, CABG, valve surgery, or additional invasive procedures. 7. Pre-existing atrial fibrillation or prolonged QTcF (470ms in men, 480ms in women). 8. Anticipated requirement for oral anticoagulants before Day 30. 9. CRUSADE bleeding risk score \>40. 10. Suspected aortic dissection. 11. History of gastrointestinal or genitourinary bleeding within the previous 3 months. 12. Refusal to receive blood transfusion if needed during the study. 13. Major surgery in the last month. 14. History of heparin-induced thrombocytopenia and bleeding diathesis. 15. Severe uncontrolled hypertension. 16. Prior (within 30 days prior to enrollment) or planned administration of thrombolytics, glycoprotein IIb/IIIa inhibitors, bivalirudin, or fondaparinux for the index MI. 17. Known relevant hematological deviations: hemoglobin (male) \< 11 g/dL, hemoglobin (female) \< 10 g/dL, hematocrit \< 35%, platelet count \< 100,000 cells/µL. 18. Use of Coumadin derivatives and/or Factor Xa inhibitor drugs within the last 7 days. 19. Chronic therapy with non-steroidal anti-inflammatory drugs (NSAIDs; except aspirin) , cyclooxygenase (COX)-2 inhibitors within 1 month before screening. 20. Known malignancies or other comorbid conditions with life expectancy \< 1 year. 21. Known severe liver disease (i.e., aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\] \> 3 × ULN). 22. Known positive serology for hepatitis B \& C, HIV screen. 23. Known chronic kidney disease with estimated glomerular filtration rate (eGFR) \<30 mL/min and/or dialysis. 24. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, bivalirudin, unfractionated heparin, P2Y12 antagonists, or contrast.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Co-Primary Composite Endpoint | During PCI on day 1, and up to 30 days follow up | Composite of: 1. achievement of target ACT (200-300 sec) on MT1002 without switching to standard of care from the start of coronary angiography through the end of the PCI procedure (up to 4 hours of continuous infusion), and successful PCI; 2. occurrence of BARC Type 3-5 major bleeding events from initiation of study drug through 30 days post-PCI. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Cardiovascular Events (MACE) | 30 days | MACE is defined as nonfatal MI, unplanned revascularization (PCI or CABG) of the ischemic target vessel including intraprocedural stent thrombosis, re-hospitalization for a CV-related condition, nonfatal stroke, CV death, and all-cause mortality. |
Countries
United States
Participant flow
Recruitment details
12 patients were screended, 6 patients were enrolled into the first dose group and dosed of MT1002 0.90mg/kg bonus+1.8mg/kg/h×4h infusion.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 65.7 Years |
| CRUSADE Bleeding Risk Score CRUSADE Bleeding Risk Score ≤20 | 4 Participants |
| CRUSADE Bleeding Risk Score CRUSADE Bleeding Risk Score from 31-40 | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 6 |
| other Total, other adverse events | 2 / 6 |
| serious Total, serious adverse events | 0 / 6 |
Outcome results
None listed